📰 Therapeutic Development Programs News
Page 3 - Therapeutic Development Programs News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Therapeutic Development Programs. Real-time updates on events, politics, business and more.
September 14, 2023
StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report published on Sunday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB opened at $0.11 on Friday. The firm has a market cap of $11.38 million, a PE ratio of -0.39 and a beta of […]
September 6, 2023
StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report report published on Saturday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Trading Up 23.4 % Shares of NAVB opened at $0.10 on Friday. Navidea Biopharmaceuticals has a 12 month low of $0.06 and a 12 […]
August 29, 2023
StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report released on Friday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance NYSE NAVB opened at $0.08 on Friday. Navidea Biopharmaceuticals has a 1 year low of $0.06 and a 1 year high of $0.39. The […]
August 12, 2023
StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB opened at $0.08 on Wednesday. The company’s 50 day simple moving average is $0.09 and its two-hundred day simple moving […]
August 5, 2023
StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report issued on Tuesday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Shares of NYSE:NAVB opened at $0.07 on Tuesday. Navidea Biopharmaceuticals has a twelve month low of $0.07 and a twelve month high of […]
August 5, 2023
StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance NYSE:NAVB opened at $0.07 on Tuesday. Navidea Biopharmaceuticals has a one year low of $0.07 and a one year high of $0.62. […]
July 10, 2023
A number of research firms have changed their ratings and price targets for Navidea Biopharmaceuticals (NYSE: NAVB): 7/8/2023 – Navidea Biopharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 6/30/2023 – Navidea Biopharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. […]
July 4, 2023
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 570,200 shares, a drop of 35.3% from the May 31st total of 881,100 shares. Currently, 4.5% of the company’s shares are short sold. Based […]
July 4, 2023
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totalling 570,200 shares, a decline of 35.3% from the May 31st total of 881,100 shares. Based on an average daily trading volume, of 5,430,000 shares, the short-interest ratio […]
July 4, 2023
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 570,200 shares, a decline of 35.3% from the May 31st total of 881,100 shares. Based on an average daily volume of 5,430,000 shares, the […]